Mai Capital Management Supernus Pharmaceuticals, Inc. Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mai Capital Management holds 29 shares of SUPN stock, worth $1,003. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29Holding current value
$1,003% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$359 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$213 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$167 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$99.6 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$90.9 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.85B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...